Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday.Investors acquired 23,699 call options on the company. This is an ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that soared on Friday. Wall Street finished mixed anew on Friday ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market may have registered losses on Friday ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $8.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

The last time I wrote about Recursion Pharmaceuticals (NASDAQ:RXRX) it was with respect to a Seeking Alpha article entitled "Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC ...

Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX ... and the technology-dominated Nasdaq saw an increase of 1.51%. The the stock of biotechnology company has risen ...

In the latest trading session, Recursion Pharmaceuticals (RXRX ... Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq lost 0.36%. Coming into today, shares of the biotechnology company ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other best performing pharma stocks so far in 2025. On February 20 ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 ...